# US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism

Study · id `cardio:ct-nct05127915` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05127915](<https://clinicaltrials.gov/study/NCT05127915>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05127915

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 854 participants.

## Technical summary

Registry record NCT05127915. Randomized; single masking; primary purpose prevention. Start 2023-01-27 (actual); primary completion 2026-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 854 participants (planned count; ClinicalTrials.gov record NCT05127915, source copy `cardio:ctgov-nct05127915-2023-08-31`, retrieved 2026-10-31)
- Started: 2023-01-27 (actual) (ClinicalTrials.gov record NCT05127915, source copy `cardio:ctgov-nct05127915-2023-08-31`, retrieved 2026-10-31)
- Primary completion: 2026-05-31 (anticipated) (ClinicalTrials.gov record NCT05127915, source copy `cardio:ctgov-nct05127915-2023-08-31`, retrieved 2026-10-31)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05127915, source copy `cardio:ctgov-nct05127915-2023-08-31`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT05127915, source copy `cardio:ctgov-nct05127915-2023-08-31`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05127915-2023-08-31`, retrieved 2026-10-31)

## The registry's words

- Brief title: US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism
- Condition: Pulmonary Embolism
- Intervention (Device): Adient absorbable filter + best practice VTE prophylaxis
- Intervention (Device): best practice VTE prophylaxis
- Lead sponsor: Adient Medical
- Lead sponsor class: INDUSTRY
- Collaborator: Avania
- Collaborator class: INDUSTRY
- Collaborator: ICON plc
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as a collaborator: Avania (`cardio:org-avania`)
- Registry lists this organization as a collaborator: ICON plc (`cardio:org-icon-plc`)

## Provenance

Content hash: 678e63ce8bb6e22c7f05f2c71bf05609b71d1d75b43d28edee9f084b41836553
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
